Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prisotinol SCHEMBL9626289 | 0.98 | ESR1 (0.57) | ESR1ESR2CYP1A2CYP2D6APEX1 | |
| Prisotinol SCHEMBL9625100 | 0.89 | ESR1 (0.48) | ESR1ESR2APEX1DEGS1HCAR2 | |
| Prisotinol SCHEMBL9625103 | 0.89 | ESR1 (0.48) | ESR1ESR2APEX1DEGS1HCAR2 | |
| Hydrochloric Acid SCHEMBL11099544 | 0.83 | ESR1 (0.58) | ESR1ESR2CYP2D6SLC6A4DEGS1 | |
| Hydrochloric Acid SCHEMBL11123301 | 0.82 | ESR1 (0.46) | ESR1ESR2CYP1A2CYP2D6PMP22 | |
| SCHEMBL11128368 | 0.81 | ESR1 (0.57) | ESR1ESR2CYP2D6SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL11375607 | 0.81 | ESR1 (0.53) | ESR1ESR2SLC6A4DEGS1HCAR2 | |
| SCHEMBL17996823 | 0.80 | ESR1 (0.68) | ESR1ESR2DEGS1TAAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL11099068 | 0.79 | ESR1 (0.54) | ESR1ESR2DEGS1 | |
| SCHEMBL11097229 | 0.79 | ESR1 (0.54) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| WO-2014134005-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-08-28 | — | — | US | claimed |
| CN-101486668-B | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC | 2014-07-02 | — | — | CN | claimed |
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-8062870-B2 | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs | XENOPORT, INC. (US) | 2011-11-22 | — | — | US | claimed |
| EP-0241428-B1 | USE OF 2-AMINOALKYL-5-PYRIDINOL COMPOUNDS AS NOOTROPICS AND ANTIDEPRESSANTS | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | claimed |
| US-4746670-A | Use of 2-aminoalkyl-5-pyridinols as nootropic agents and antidepressants | CIBA-GEIGY CORPORATION (US) | 1988-05-24 | — | — | US | claimed |
| EP-0241428-A2 | Use of 2-aminoalkyl-5-pyridinol compounds as nootropics and antidepressants | CIBA-GEIGY AG (CH) | 1987-10-14 | — | — | EP | claimed |
| EP-0019739-B1 | 2-AMINOALKYL-5-PYRIDINOLES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1984-07-18 | — | — | EP | claimed |
| US-4260619-A | ANTIISCHEMIC | CIBA-GEIGY CORPORATION (US) | 1981-04-07 | — | — | US | claimed |
| EP-0019739-A1 | 2-Aminoalkyl-5-pyridinoles, process for their preparation and pharmaceutical preparations containing them | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| EP-0241428-A2 | Use of 2-aminoalkyl-5-pyridinol compounds as nootropics and antidepressants | CIBA-GEIGY AG (CH) | 1987-10-14 | — | — | EP | disclosed |
| EP-0019739-B1 | 2-AMINOALKYL-5-PYRIDINOLES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1984-07-18 | — | — | EP | disclosed |
| US-4260619-A | ANTIISCHEMIC | CIBA-GEIGY CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
| EP-0019739-A1 | 2-Aminoalkyl-5-pyridinoles, process for their preparation and pharmaceutical preparations containing them | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | ESR1 2669/4885ESR2 3533/4885CYP1A2 311/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ESR1 2396/4885ESR2 1128/4885CYP1A2 185/4885 |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | ESR1 2669/4885ESR2 3533/4885CYP1A2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.